Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
Top Cited Papers
- 13 March 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (6), 1316-1323
- https://doi.org/10.1200/jco.2000.18.6.1316
Abstract
PURPOSE: This multicenter phase II study evaluated the efficacy, dosimetry methodology, and safety of iodine-131 tositumomab in patients with chemotherapy-relapsed/refractory low-grade or transform...Keywords
This publication has 24 references indexed in Scilit:
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow SupportNew England Journal of Medicine, 1993
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Tolerance of normal tissue to therapeutic irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Stage I and II non-hodgkin's lymphomas: Long-term results of radiation therapyInternational Journal of Radiation Oncology*Biology*Physics, 1989
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasNew England Journal of Medicine, 1984
- Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril (Iodogen)Analytical Biochemistry, 1981
- No Initial Therapy for Stage III and IV Non-Hodgkin's Lymphomas of Favorable Histologic TypesAnnals of Internal Medicine, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958